Skip to main content
Premium Trial:

Request an Annual Quote

Quantgene, Vikor Scientific Partner to Launch Genomics Health Service

NEW YORK – Molecular diagnostics firm Vikor Scientific has made a strategic investment in California-based Quantgene to accelerate the commercialization of Quantgene's Serenity, a personalized preventive medicine service that includes the use of whole-genome sequencing, artificial intelligence-informed liquid biopsy cancer screening, and other in-depth health profiling.

The companies made the announcement on Wednesday during the SCBIO 2021 annual meeting. Financial details of the deal were not disclosed.

Quantgene describes Serenity as a direct-to-consumer concierge medical service that is intended to improve users' health by assessing their genetic and other disease risk factors, providing regular reanalysis based on evolution of the medical literature. This is coupled with serial blood-based monitoring for early signs of cancer.

In their announcement, the partners said that they also plan to add to the current service with additional liquid biopsy products including minimal residual disease and recurrence monitoring assays for patients with an already diagnosed cancer, as well as unspecified companion diagnostics.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.